

## Special Issue

# Recent Advances in Interstitial Lung Disease

### Message from the Guest Editor

A complete score, including all principal variables used to stratify idiopathic pulmonary fibrosis (IPF) patients, is currently lacking. Moreover, there is no standard definition of disease progression and no decline rate has been formally accepted in patients with IPF. At present, scores are only limited to a comparison between IPF and one or two variables (such as pulmonary function tests, high-resolution computed tomography, or acute exacerbation) which are evaluated singularly. In addition, pulmonary hypertension is underestimated or not considered in IPF data analysis. According to the literature, we suggest dividing all risk predictors into:

- probable predictors;
- potential predictors.

On the basis of the severity of each risk factor on IPF outcome, we also aim to:

- define the worse predictive risk factors in IPF;
- propose an accurate and complete predictor risk score of poor outcome with all principal variables;
- identify a standard definition of disease progression;
- enable clinicians to better evaluate eligibility criteria for anti-fibrotic therapy or lung transplantation strategies in clinical practice.

---

### Guest Editor

Prof. Dr. Roberto Carbone

Department of Internal Medicine, University of Genoa, Genoa, Italy

---

### Deadline for manuscript submissions

closed (20 November 2024)



## Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/187492](https://mdpi.com/si/187492)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
jcm](https://mdpi.com/journal/jcm)



## About the Journal

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67000  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).